Venous thromboembolism (VTE) is a major cause of morbidity and mortality in patients with cancer. For over a decade, the gold standard of treatment and secondary prevention of cancer-associated thrombosis (CAT) has been represented by low-molecular-weight heparins (LMWHs), which are currently recommended as the first-line treatment for CAT. Among the LMWHs that were more extensively tested in patients with CAT, tinzaparin is a LMWH produced by the enzymatic degradation of porcine-derived unfractionated heparin. The efficacy of tinzaparin in this setting is supported by well-grounded evidence. However, there is a need to discuss the positioning of tinzaparin in the continuously evolving treatment scenario of VTE therapy in cancer patients. In this paper, which was developed by a group of clinicians with wide experience in the treatment of VTE in cancer patients, we discuss the current therapeutic options and the role of tinzaparin for the treatment of CAT.

Ageno, W., Barni, S., Di Nisio, M., Falanga, A., Imberti, D., Labianca, R., et al. (2019). Treatment of venous thromboembolism with tinzaparin in oncological patients. MINERVA MEDICA, 110(3), 251-258 [10.23736/S0026-4806.19.06026-9].

Treatment of venous thromboembolism with tinzaparin in oncological patients

Falanga, Anna;Mantovani, Lorenzo
Ultimo
2019

Abstract

Venous thromboembolism (VTE) is a major cause of morbidity and mortality in patients with cancer. For over a decade, the gold standard of treatment and secondary prevention of cancer-associated thrombosis (CAT) has been represented by low-molecular-weight heparins (LMWHs), which are currently recommended as the first-line treatment for CAT. Among the LMWHs that were more extensively tested in patients with CAT, tinzaparin is a LMWH produced by the enzymatic degradation of porcine-derived unfractionated heparin. The efficacy of tinzaparin in this setting is supported by well-grounded evidence. However, there is a need to discuss the positioning of tinzaparin in the continuously evolving treatment scenario of VTE therapy in cancer patients. In this paper, which was developed by a group of clinicians with wide experience in the treatment of VTE in cancer patients, we discuss the current therapeutic options and the role of tinzaparin for the treatment of CAT.
Articolo in rivista - Articolo scientifico
Cancer associated thrombosis
English
2019
110
3
251
258
none
Ageno, W., Barni, S., Di Nisio, M., Falanga, A., Imberti, D., Labianca, R., et al. (2019). Treatment of venous thromboembolism with tinzaparin in oncological patients. MINERVA MEDICA, 110(3), 251-258 [10.23736/S0026-4806.19.06026-9].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/227361
Citazioni
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 5
Social impact